{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:28:05Z","timestamp":1793798885881,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hrthm.2026.09.051","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:46:24Z","timestamp":1791330384000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of flecainide vs amiodarone for the cardioversion of paroxysmal atrial fibrillation in patients with coronary artery disease without evidence of residual ischemia: The FLECA-ED randomized clinical trial"],"prefix":"10.1016","author":[{"given":"Panagiotis-Anastasios","family":"Tsioufis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tsiachris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Argyriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Botis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Doundoulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Kordalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos-Konstantinos","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos","family":"Matthaiopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Zamanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Mihas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Xydonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Patsilinakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kafkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Gatzoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-6725","authenticated-orcid":false,"given":"\u039aonstantinos","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2026.09.051_bib1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.09.051_bib2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.09.051_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.121.010321","article-title":"Pharmacological cardioversion of atrial tachyarrhythmias using single high-dose oral amiodarone: a systematic review and meta-analysis","volume":"14","author":"Lei","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.09.051_bib4","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.3390\/jcm12123961","article-title":"Rationale and design of a randomized controlled clinical trial on the safety and efficacy of Flecainide versus Amiodarone in the cardioversion of Atrial Fibrillation at the Emergency Department in patients with Coronary Artery Disease (FLECA-ED)","volume":"12","author":"Tsioufis","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.hrthm.2026.09.051_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes [published correction appears in Eur Heart J 2020;41:4242]","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.09.051_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.09.051_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10557-020-07127-1","article-title":"Pharmacologic cardioversion in patients with paroxysmal atrial fibrillation: a network meta-analysis","volume":"35","author":"Tsiachris","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hrthm.2026.09.051_bib8","series-title":"Design and Analysis of Clinical Trials: Concepts and Methodologies","author":"Chow","year":"2014"},{"key":"10.1016\/j.hrthm.2026.09.051_bib9","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0002-9149(02)02867-9","article-title":"Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol\/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study)","volume":"90","author":"Meinertz","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2026.09.051_bib10","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1161\/01.CIR.90.6.2843","article-title":"Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST)","volume":"90","author":"Anderson","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.09.051_bib11","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/0002-9149(91)90308-8","article-title":"Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. Cast Investigators","volume":"68","author":"Akiyama","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2026.09.051_bib12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/hrt.74.6.631","article-title":"Interaction of ischaemia and encainide\/flecainide treatment: a proposed mechanism for the increased mortality in CAST I","volume":"74","author":"Greenberg","year":"1995","journal-title":"Br Heart J"},{"key":"10.1016\/j.hrthm.2026.09.051_bib13","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1016\/j.hrthm.2026.02.042","article-title":"Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: safety and clinical outcomes from a nationwide cohort","volume":"23","author":"Huang","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.09.051_bib14","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.hrthm.2025.08.034","article-title":"Flecainide in structural heart diseases: a contemporary reappraisal beyond the CAST","volume":"23","author":"Genovese","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.09.051_bib15","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jacep.2022.12.021","article-title":"The feasibility and safety of flecainide use among patients with varying degrees of coronary disease","volume":"9","author":"Kiani","year":"2023","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.09.051_bib16","doi-asserted-by":"crossref","first-page":"e1387","DOI":"10.1016\/j.hrthm.2025.09.030","article-title":"Expanding the indications for flecainide: good idea or CAST reprise?","volume":"23","author":"Kowey","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.09.051_bib17","doi-asserted-by":"crossref","first-page":"e1383","DOI":"10.1016\/j.hrthm.2026.02.010","article-title":"Flecainide use before and after the Cardiac Arrhythmia Suppression Trial: a systematic review","volume":"23","author":"Li","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.09.051_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2026.07.012","article-title":"2026 HRS\/PACES scientific statement on the use of antiarrhythmic drugs in understudied clinical scenarios","author":"Morin","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.09.051_bib19","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0735-1097(95)00595-1","article-title":"Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study","volume":"27","author":"Galve","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.09.051_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0735-1097(02)02705-5","article-title":"Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis","volume":"41","author":"Chevalier","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.09.051_bib21","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0002-9149(00)01128-0","article-title":"Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm","volume":"86","author":"Mart\u00ednez-Marcos","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2026.09.051_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5811\/westjem.2012.1.6893","article-title":"Impact of emergency department management of atrial fibrillation on hospital charges","volume":"14","author":"Sacchetti","year":"2013","journal-title":"West J Emerg Med"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126028559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126028559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:43:56Z","timestamp":1793796236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527126028559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S1547527126028559"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.09.051","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of flecainide vs amiodarone for the cardioversion of paroxysmal atrial fibrillation in patients with coronary artery disease without evidence of residual ischemia: The FLECA-ED randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.09.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}